---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009967"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T15:59:53.848202+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma restates FY2024 financials; prior statements not reliable

## Summary
- Non-reliance on unaudited FY2024 financials filed Nov 20, 2024; share compensation and derivative liability corrected.
- Derivative liability increased by $6,816; total liabilities restated to $5.38M.
- Net loss restated from $809,255 to $668,255, improvement of $198,995.
- Prepaid assets reduced by $16,527; total assets restated to $161,084.
- Additional paid-in capital decreased by $17,492; AOCI shows negative $204,847 from reclassification.

## SEC filing metadata
- accession: 0001641172-25-009967
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000164117225009967/0001641172-25-009967-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000164117225009967/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009967
- JSON: https://secwatch.observer/filing/0001641172-25-009967.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009967.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.